STERIS Earnings Call Highlights Record Year and Cautious Outlook

Steris ((STE)) has held its Q4 earnings call. Read on for the main highlights of the call.

STERIS struck an upbeat tone on its latest earnings call, framing fiscal 2026 as a record year despite visible headwinds from tariffs, taxes, and uneven demand in parts of its portfolio. Management highlighted double‑digit adjusted EPS growth, robust cash generation, and a fortress-like balance sheet, while acknowledging margin pressure in the fourth quarter and a step down in free cash flow expected for fiscal 2027.

Record Fiscal 2026 Revenue and Earnings

STERIS reported fiscal 2026 revenue of about $6.0 billion, up 9% year over year with roughly 7% constant-currency organic growth, underscoring broad-based demand across its core markets. Adjusted diluted EPS climbed to $10.17, representing 10% growth and signaling the company’s ability to convert top-line gains into solid bottom-line performance.

Strong Fourth Quarter Top-Line

Fourth-quarter revenue increased 7% as reported and 5% on a constant-currency organic basis, fueled by both volume and about 230 basis points of pricing. Adjusted net income from continuing operations reached $278.3 million, with adjusted diluted EPS of $2.83 up 3% versus the prior-year period, even as margins compressed.

Exceptional Free Cash Flow and Balance Sheet Strength

Free cash flow for fiscal 2026 was described as exceptional at $982.9 million, giving STERIS ample flexibility for investment and returns to shareholders. The company ended the year with $1.9 billion of total debt and gross debt to EBITDA of roughly 1.2x, well below its 2.0–2.5x target range and indicative of a very conservative leverage profile.

Margin Resilience Amid Tariffs and Inflation

Despite inflationary pressures and incremental tariffs, total company EBIT margin in fiscal 2026 expanded by 10 basis points to 23.3%, demonstrating notable cost discipline. Management estimated that higher tariffs alone cost about $46 million and shaved roughly 80 basis points off margins, yet the company still delivered overall margin improvement.

Segment Milestones and Balanced Growth

Healthcare led the portfolio with 9% revenue growth, or 8% constant-currency organic, driven by double‑digit service growth and steady consumables demand, generating roughly $4 billion of revenue and $1 billion of operating income. AST and Life Sciences each delivered around 9–10% growth, with AST surpassing $1 billion in revenue and $500 million in operating profit and Life Sciences topping $250 million in operating profit on strong capital equipment and consumables sales.

Capital Allocation and Shareholder Returns

The board approved a 6‑cent increase in the quarterly dividend to $0.63, marking the 20th consecutive year of dividend growth, reinforcing a consistent income proposition for investors. STERIS also completed $225 million of share repurchases in fiscal 2026 and secured a new $1 billion buyback authorization, with management planning to buy back $200–$300 million of stock per year.

Strategic Investments and M&A

The company completed two tuck-in Healthcare acquisitions expected to contribute roughly $45 million of revenue in fiscal 2027, bolstering its service and consumables offerings. STERIS is also committing around $60 million over two years to build a new sterility assurance manufacturing plant in Ohio and launching AI-enabled service workflow upgrades aimed at improving productivity and service quality.

Margin Pressure in Q4 and Tax Headwinds

Fourth-quarter profitability showed some strain, with gross margin slipping 30 basis points to 44% and EBIT margin falling 60 basis points versus the prior-year quarter, even though the absolute EBIT margin of 24.2% was a fiscal-year high for any quarter. Tax dynamics also turned less favorable, as the adjusted effective tax rate climbed to 25.4% in Q4 and 24.4% for the full year, up 130 basis points year on year, creating a drag on EPS growth.

Tariff Costs and Ongoing Margin Risk

Tariffs remain a meaningful cost headwind, with total tariff spend in fiscal 2026 estimated at about $60–65 million and incremental tariffs alone hitting $46 million. Management’s fiscal 2027 outlook assumes a similar tariff burden and explicitly excludes any potential refunds, leaving little relief from this structural margin pressure in the near term.

AST Softness and Inventory Headwinds

While the AST segment delivered double-digit growth for the year, the second half and especially the fourth quarter were softer than expected, partly due to severe U.S. snowstorms that shaved an estimated 150–200 basis points off growth. In addition, med‑tech customers are managing down inventories, creating choppy demand patterns and tougher year-over-year comparisons early in fiscal 2027 for this high-margin business.

Free Cash Flow Forecast Moderation

Management cautioned that free cash flow is likely to moderate in fiscal 2027 to about $850 million, down roughly 13–14% from fiscal 2026’s exceptional level. The expected decline reflects higher working capital tied to growth, around $50 million of increased incentive compensation payments, and remaining settlement-related outflows rather than structural deterioration in the underlying business.

Buyback Execution Constrained by Tax Frictions

Although STERIS has ample balance sheet capacity, management noted that cross-border cash movements trigger withholding taxes and other frictions, reducing the efficiency of large, rapid buybacks. These tax dynamics influenced the decision to target a steady pacing of $200–$300 million of annual repurchases instead of more aggressive, one-time programs, favoring consistency over opportunism.

Ongoing Cost and Supply Risks

The company acknowledged continued exposure to inflation in freight, energy, and raw materials—particularly metals, plastics, and chemicals tied to oil—that make up a significant slice of its cost of goods. Management also warned that prolonged geopolitical disruptions or further energy price spikes could add incremental margin pressure, as guidance does not assume relief from tariffs or changes in trade frameworks.

Guidance Signals Disciplined Growth in FY2027

For fiscal 2027, STERIS guided as‑reported revenue growth of 7–8% and constant-currency organic growth of 6–7%, supported by roughly 200 basis points of price and about $45 million from recent acquisitions, with all three segments expected to expand at mid‑single to high‑single‑digit rates. Management is targeting around 50 basis points of EBIT margin expansion, an adjusted tax rate near 25%, adjusted EPS of $11.10–$11.30 implying 9–11% growth, and free cash flow of roughly $850 million alongside elevated capital spending and steady buybacks.

STERIS’s latest earnings call painted the picture of a high-quality operator balancing record performance with transparent acknowledgment of rising tariffs, taxes, and cost risks. For investors, the combination of consistent revenue growth, disciplined capital allocation, and a measured but constructive outlook for fiscal 2027 suggests the company remains well-positioned, even if free cash flow eases from last year’s peak and near-term margin volatility persists.